Gemina Laboratories Stock Net Income

GLABF Stock  USD 0.55  0.01  1.79%   
Gemina Laboratories fundamentals help investors to digest information that contributes to Gemina Laboratories' financial success or failures. It also enables traders to predict the movement of Gemina OTC Stock. The fundamental analysis module provides a way to measure Gemina Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gemina Laboratories otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gemina Laboratories OTC Stock Net Income Analysis

Gemina Laboratories' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Gemina Laboratories Net Income

    
  (4.73 M)  
Most of Gemina Laboratories' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gemina Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Gemina Laboratories reported net income of (4.73 Million). This is 101.39% lower than that of the Healthcare sector and 106.76% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.83% higher than that of the company.

Gemina Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gemina Laboratories' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Gemina Laboratories could also be used in its relative valuation, which is a method of valuing Gemina Laboratories by comparing valuation metrics of similar companies.
Gemina Laboratories is currently under evaluation in net income category among its peers.

Gemina Fundamentals

About Gemina Laboratories Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Gemina Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gemina Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gemina Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Gemina OTC Stock

Gemina Laboratories financial ratios help investors to determine whether Gemina OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gemina with respect to the benefits of owning Gemina Laboratories security.